|Bid||32.01 x 800|
|Ask||52.60 x 800|
|Day's Range||32.00 - 33.67|
|52 Week Range||20.72 - 55.49|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2020 - Mar 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.38|
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units ("RSUs") to five new employees in connection with their employment with Urogen. These new team members will support pre-launch activities and infrastructure buildout as the Company prepares for potential approval and commercial launch of its first product candidate.
UroGen Pharma Ltd. , a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will participate
Completed Submission of New Drug Application to U.S. FDA for UGN-101 in Patients with Low-Grade Upper Tract Urothelial Cancer
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...
UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered into an exclusive worldwide1 license agreement with Agenus Inc (AGEN) to develop and commercialize zalifrelimab (AGEN1884, anti-CTLA-4 antibody) via intravesical delivery in combination with UGN-201 for the treatment of urinary tract cancers. This combination is based on encouraging preclinical data utilizing UroGen’s proprietary sustained release technology, which is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option while minimizing systemic exposure and potential side effects. UroGen’s initial indication for development will be high-grade non-muscle invasive bladder cancer (HG NMIBC).
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
UroGen Pharma Ltd. , a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will present at t
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
Wall Street, and most investors who follow its lead, is overlooking this online bank, pharmaceutical company, and master limited partnership. Investors who are paying attention could score outsized gains by investing ahead of the crowd.